The Wealth Empire report comes out every week,
check your inbox for direct access.
Last week I mentioned how concerned analysts and journalists were at the "advanced" age of this eight-year, six-month-old bull market - though, in fairness, these same folks were fretting about age when the bull turned four... five... six...
Now, age is certainly something to keep in mind (preferably at the back of your mind) when you're in the markets, but by no means should it be the thing driving your thinking or trading.
Sometimes, the greatest opportunities are hiding in plain sight.
Yet, they’re ignored, or “left for dead” out of fear that a sector may be too speculative. Biotech and pharmaceutical stocks are the perfect examples. But only the foolish have ignored the rewards the sector has produced… and will produce.
Trading theories are a dime a dozen.
The first half of the year tends to bring in better returns than the second half, we’re told. Psychologists believe that markets in the northern and southern hemispheres predictably succumb to the winter blues, or Seasonal Affective Disorder.
Exchange-traded funds have always offered more of a bang for your buck.
If I wanted to buy 10 shares of Alphabet (GOOG), Facebook (FB), Amazon.com (AMZN) and Netflix (NFLX) right now, it’d cost me $22,210.
However, with an ETF like the Advisor Shares New Tech and Media ETF (FNG), I can gain exposure to those same stocks for $19.88 a share, or $1,988. That’s a savings of more than $20,000 for similar exposure.